enGene Therapeutics Inc. Capital Expenditures
enGene Therapeutics Inc. (ENGN) reported Capital Expenditures of $251.00 thousand for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-09-08
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-07-31 was $0.00, a 100.00% decline year-over-year.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-04-30 was $98.00K, a 117.78% increase year-over-year.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-01-31 was $153.00K, a 48.83% decline year-over-year.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-10-31 was $437.00K, a 83.61% increase year-over-year.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $1.49M, a 60.54% increase from fiscal 2024.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $925.00K, a 190.88% increase from fiscal 2023.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $318.00K, a 107.84% increase from fiscal 2022.
- enGene Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $153.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | $98.00K derived: sum of 2 quarters · filed 2026-09-08 | $251.00K 10-Q · filed 2026-09-08 | $688.00K derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | $251.00K 10-Q · filed 2026-06-15 | $688.00K derived: sum of 3 quarters · filed 2026-06-15 | $1.39M derived: sum of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | $153.00K 10-Q · filed 2026-03-09 | $590.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.29M derived: sum of 3 quarters · filed 2026-09-08 | $1.34M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $1.14M derived: sum of 2 quarters · filed 2026-09-08 | $1.19M derived: sum of 3 quarters · filed 2026-09-08 | $1.49M 10-K · filed 2025-12-22 |
| 2025-07-31 | $704.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | $749.00K derived: sum of 2 quarters · filed 2026-09-08 | $1.05M 10-Q · filed 2026-09-08 | $1.29M derived: sum of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-15 | $344.00K 10-Q · filed 2026-06-15 | $582.00K derived: sum of 3 quarters · filed 2026-06-15 | $584.00K derived: sum of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | $299.00K 10-Q · filed 2026-03-09 | $537.00K derived: sum of 2 quarters · filed 2026-03-09 | $539.00K derived: sum of 3 quarters · filed 2026-03-09 | $718.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | $240.00K derived: sum of 2 quarters · filed 2025-12-22 | $419.00K derived: sum of 3 quarters · filed 2025-12-22 | $925.00K 10-K · filed 2025-12-22 |
| 2024-07-31 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-11 | $181.00K derived: sum of 2 quarters · filed 2025-09-11 | $687.00K 10-Q · filed 2025-09-11 | $825.00K derived: sum of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | $179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-06-12 | $685.00K 10-Q · filed 2025-06-12 | $823.00K derived: sum of 3 quarters · filed 2025-06-12 | $980.00K derived: sum of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | $506.00K 10-Q · filed 2025-03-10 | $644.00K derived: sum of 2 quarters · filed 2025-03-10 | $801.00K derived: sum of 3 quarters · filed 2025-03-10 | $811.00K derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | $295.00K derived: sum of 2 quarters · filed 2024-12-19 | $305.00K derived: sum of 3 quarters · filed 2024-12-19 | $318.00K 10-K · filed 2024-12-19 |
| 2023-07-31 | $157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-10 | $167.00K derived: sum of 2 quarters · filed 2024-09-10 | $180.00K 10-Q · filed 2024-09-10 | |
| 2023-04-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-06-14 | $23.00K 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | $13.00K 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | $153.00K 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |